z-logo
Premium
AuNPs Decorated PLA Stereocomplex Micelles for Synergetic Photothermal and Chemotherapy
Author(s) -
Fan Xiaoshan,
Luo Zheng,
Ye Enyi,
You Mingliang,
Liu Minting,
Yun Ye,
Loh Xian Jun,
Wu YunLong,
Li Zibiao
Publication year - 2021
Publication title -
macromolecular bioscience
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.924
H-Index - 105
eISSN - 1616-5195
pISSN - 1616-5187
DOI - 10.1002/mabi.202100062
Subject(s) - nanocarriers , photothermal therapy , micelle , ethylene glycol , materials science , drug delivery , nanoparticle , nanotechnology , photothermal effect , methacrylate , chemistry , copolymer , polymer , organic chemistry , aqueous solution , composite material
A unique platform for combined photothermal and chemotherapy using PLA stereocomplex (PLA SC) micelles‐induced hybrid gold nanocarriers is designed. The PLA SC micelles, made from the self‐assembly of poly(ethylene glycol)‐block‐poly( l ‐lactide) (PEG‐PLLA) and poly(2‐(dimethylamino) ethyl methacrylate)‐block‐poly( d ‐lactide) (PDMAEMA‐PDLA), for the first time are used as a template to fabricate the hybrid PLA SC@Au core–shell nanocarriers, in which the anticancer drugs are encapsulated within the core, while the Au nanoparticles are tethered in the shell via the in situ reduction of AuCl 4 − by PDMAEMA. The obtained PLA SC@Au hybrid nanocarriers exhibit low toxicity and remarkable photothermal effect. Upon near‐infrared laser irradiation, the on‐site photothermal therapy can further induce an accelerated drug release from the hybrid nanocarrier reservoir via hyperthermia heating of the nanocarriers, thus leading to a synergistic photothermal and chemotherapy toward a significantly improved efficacy in tumor shrinkage. The as‐designed PLA SC@Au hybrid nanocarriers, with their biocompatible compositions, dual‐drug delivery characteristics, and combined photothermal/chemotherapy, show high potential as a novel platform for cancer treatment.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here